Trace Amine-Associated Receptors as Emerging Therapeutic Targets
Open accessAbstract
Endogenous trace amines (TAs) of unknown biological function are structurally related to classic monoaminergic neurotransmitters and found at low concentrations in the mammalian brain. Their recently discovered group of G protein-coupled receptors, trace amine-associated receptors (TAARs), may represent putative targets not only for trace and other amines but also for a variety of monoaminergic compounds, including amphetamines and monoamine metabolites. The trace amine-associated receptor 1 (TAAR1), which is in part associated with the monoaminergic neuronal circuitry controlling various functions, including movement, is the best characterized of the class, although little is known about its regulation and function. Here we review the pharmacology and biochemical properties of the TAAR1 and its physiological functions as revealed in studies involving knockout mice lacking this receptor. Potential therapeutic applications of future selective TAAR1 agonists and antagonists are also discussed. Although understanding of biology and functions mediated by other TAARs is still in its infancy, it is expected that further characterization of the functional roles and biochemical properties of TAARs and identification of endogenous and exogenous ligands will eventually promote these receptors as an attractive class of targets to correct monoaminergic processes that could be dysfunctional in a host of disorders of brain and periphery.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
LDX is a specific agonist of TAAR1, a protein involved in DA pathway modulation.
“LDX is also a specific agonist of TAAR1 [169], a protein involved in DA pathway modulation [170].”
From Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review (2022) · cites this paper as [170]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited by
Sorted by citations
De Gregorio, D., Posa, L., Ochoa-Sanchez, R., McLaughlin, R., Maione, S., Comai, S., & Gobbi, G. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.022 · Cited by 110 · see citing works
Quintero, J., Gutiérrez-Casares, J. R., & Álamo, C. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00392-2 · Cited by 70 · see citing works
“LDX is also a specific agonist of TAAR1 [169], a protein involved in DA pathway modulation [170].”
BackgroundFrom neurons to brain networks, pharmacodynamics of stimulant medication for ADHD
Parlatini, V., Bellato, A., Murphy, D., & Cortese, S. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105841 · Cited by 26 · see citing works
- Authors
- Sotnikova, T. D., Caron, M. G., & Gainetdinov, R. R.
- Affiliations
- Duke University (US)
- Corresponding author
- Gainetdinov, Raul R.
- Venue
- Molecular Pharmacology
- Publisher
- Elsevier BV
- Published
- 2009-08
- Volume
- 76
- Issue
- 2
- Pages
- 229-235
- ISSN
- 0026-895X (ISSN-L)
- PMC
- PMC2713119
- OpenAlex
- W2152415721
- Cited by
- 97
- References
- 0
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 7 · 2022: 8 · 2021: 1 · 2020: 3 · 2019: 3 · 2018: 7 · 2017: 4 · 2016: 13 · 2015: 7 · 2014: 9 · 2013: 7 · 2012: 6
- FWCI
- 0.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Molecular Pharmacology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- F. Hoffmann-La Roche
- National Institutes of Health (5u01da022950-03, NS-19576)
- National Institute on Drug Abuse (1U01-DA022950)
- National Institute of Neurological Disorders and Stroke (NS-19576, R01NS019576)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- trace amine-associated receptors, TAAR1, trace amines, G protein-coupled receptors, monoaminergic neurotransmission, amphetamine, monoamine metabolites, therapeutic target, movement disorders
- MeSH terms
- Trace Amine-Associated Receptors, Animals, Biogenic Amines, Forecasting, Mice, Knockout, Neurotransmitter Agents, Receptors, G-Protein-Coupled, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review